Metabolic Neuropathy Medication
- Author: Tarakad S Ramachandran, MBBS, FRCP(C), FACP; Chief Editor: Nicholas Lorenzo, MD more...
Medication Summary
See Medical Care for a full discussion of recent and ongoing studies and symptomatic treatment.
Gastrointestinal agents
Class Summary
These agents increase peristalsis of upper GI tract.
Metoclopramide (Clopra, Reglan, Maxolon)
Sensitizes tissue to action of acetylcholine and stimulates motility of upper GI tract; indicated for gastroparesis. In severe gastroparesis, is not absorbed and should be given IV.
Broad-spectrum antibiotics
Class Summary
Therapy must be comprehensive and cover all likely pathogens in the context of neuropathic enteropathy.
Ampicillin (Omnipen, Marcillin, Polycillin, Principen)
Bactericidal activity against susceptible organisms. Alternative to amoxicillin when unable to take medication orally.
Tetracycline (Sumycin)
Treats gram-positive and gram-negative organisms as well as mycoplasmal, chlamydial, and rickettsial infections. Inhibits bacterial protein synthesis by binding with 30S and possibly 50S ribosomal subunit(s).
Metronidazole (Flagyl, Protostat)
Imidazole ring-based antibiotic active against various anaerobic bacteria and protozoa. Used in combination with other antimicrobial agents (except for Clostridium difficile enterocolitis).
Cholinergic agents
Class Summary
These agents increase peristalsis and secretions in the intestine. They also increase contraction and relaxation of the sphincter of the bladder. They may help in treatment of cystopathy.
Bethanechol (Urecholine, Duvoid, Myotonachol)
Used for selective stimulation of bladder to produce contraction to initiate micturition and empty bladder. Most useful in patients who have bladder hypocontractility, provided they have functional and coordinated sphincters. Rarely used because of difficulty in timing effect and because of GI stimulation.
Tricyclic antidepressants
Class Summary
These agents have been shown to be effective in treating painful diabetic neuropathy. They act on CNS, preventing reuptake of norepinephrine and serotonin at synapses involved in pain inhibition. Benefits are unrelated to relief of depression.
Amitriptyline (Elavil)
Analgesic for certain types of chronic and neuropathic pain.
Nortriptyline (Aventyl HCl, Pamelor)
Has demonstrated effectiveness in treatment of chronic pain. By inhibiting reuptake of serotonin and/or norepinephrine by presynaptic neuronal membrane, this drug increases synaptic concentration of these neurotransmitters in CNS.
Pharmacodynamic effects such as desensitization of adenyl cyclase and down-regulation of beta-adrenergic receptors and serotonin receptors also appear to play roles in its mechanisms of action.
Selective serotonin reuptake inhibitors
Class Summary
These agents specifically inhibit presynaptic reuptake of serotonin but not noradrenaline.
Paroxetine (Paxil)
Effective in painful diabetic neuropathy.
Anticonvulsants
Class Summary
Use of certain anti-epileptic drugs, such as the GABA analogue gabapentin, has proven helpful in some cases of neuropathic pain. Thus, a trial of such an agent might provide analgesia for symptomatic neuropathy.
Phenytoin (Dilantin)
Blocks sodium channels nonspecifically and therefore reduces neuronal excitability in sensitized C-nociceptors. Has been demonstrated effective in neuropathic pain but suppresses insulin secretion and may precipitate hyperosmolar coma in patients with diabetes.
Carbamazepine (Tegretol)
Nonspecific sodium channel blocker that has been effective in treatment of painful diabetic neuropathy; more useful in trigeminal neuralgia.
Gabapentin (Neurontin)
Novel anticonvulsant with unknown mechanism of action; believed to antagonize glutamate excitotoxicity. Has demonstrated effectiveness in neuropathic pain, but doses in clinical trials were as high as 3600 mg.
Analgesics
Class Summary
Recent studies have demonstrated efficacy in different types of neuropathic pain.
Tramadol (Ultram)
Analgesic probably acting over both monoaminergic and opioid mechanisms. Monoaminergic effect shared with TCAs. Tolerance and dependence appear to be uncommon.
Dopamine agonists
Class Summary
In order for a dopamine agonist to offer clinical benefit, it must stimulate D2 receptors. The role of other dopamine receptor subtypes is currently unclear. They inhibit noxious input to spinal cord.
Levodopa (Depar, Larodopa)
Has actions over noradrenergic receptors.
Topical analgesics
Class Summary
Studies have demonstrated efficacy in different types of neuropathic pain. Capsaicin has been shown to have efficacy in treatment of painful diabetic neuropathy and postherpetic neuralgia.
Capsaicin (Dolorac, Zostrix)
Derived from chili peppers; depletes substance P from sensory nerves, causing chemodenervation. Has demonstrated effectiveness in several studies of diabetic neuropathic pain and in other types of neuropathic pain.
Selective serotonin and norepinephrine reuptake inhibitors (SSNRI)
Class Summary
SSNRIs have antidepressant and central pain inhibitory actions.
Duloxetine hydrochloride (Cymbalta)
The efficacy of duloxetine in the treatment of neuropathic pain associated with diabetic peripheral neuropathy was established in 2 large, randomized, placebo-controlled trials in adult patients. These studies led to duloxetine becoming the first FDA-approved agent for the treatment of diabetic neuropathic pain. Action is believed to involve inhibition of central pain mechanisms at the recommended dose of 60 mg/d PO.
Tamborlane WV, Ahern J. Implications and results of the Diabetes Control and Complications Trial. Pediatr Clin North Am. Apr 1997;44(2):285-300. [Medline].
Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA, et al. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep. Aug 2010;10(4):276-82. [Medline].
Greene DA, Stevens MJ, Feldman EL. Diabetic neuropathy: scope of the syndrome. Am J Med. Aug 30 1999;107(2B):2S-8S. [Medline].
Voulgari C, Psallas M, Kokkinos A, Argiana V, Katsilambros N, Tentolouris N. The association between cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. J Diabetes Complications. May-Jun 2011;25(3):159-67. [Medline].
Dyck PJ, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology. Dec 10 1999;53(9):2113-21. [Medline].
Harati Y. Frequently asked questions about diabetic peripheral neuropathies. Neurol Clin. Aug 1992;10(3):783-807. [Medline].
Pirart J. [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part) (author's transl)]. Diabete Metab. Dec 1977;3(4):245-56. [Medline].
Arezzo JC. New developments in the diagnosis of diabetic neuropathy. Am J Med. Aug 30 1999;107(2B):9S-16S. [Medline].
Chalk CH. Acquired peripheral neuropathy. Neurol Clin. Aug 1997;15(3):501-28. [Medline].
Dick PJ, Thomas PK, eds. Peripheral Neuropathy. 3rd ed. Philadelphia: WB Saunders Co; 1993.
Comi G, Corbo M. Metabolic neuropathies. Curr Opin Neurol. Oct 1998;11(5):523-9. [Medline].
Thomas PK, Tomlinson DR. Diabetic and hypoglycemic neuropathy. In: Dick PJ, Thomas PK, eds. Peripheral Neuropathy. Philadelphia: WB Saunders Co; 1993:1221.
Apfel SC. Neurotrophic factors in the therapy of diabetic neuropathy. Am J Med. Aug 30 1999;107(2B):34S-42S. [Medline].
Misiunas A, Niepomniszcze H, Ravera B, et al. Peripheral neuropathy in subclinical hypothyroidism. Thyroid. Aug 1995;5(4):283-6. [Medline].
Kyle RA. Monoclonal proteins in neuropathy. Neurol Clin. Aug 1992;10(3):713-34. [Medline].
Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. Mar 9 2006;354(10):1021-30. [Medline].
Simmons DN, Lisle DA, Linklater JM. Imaging of Peripheral Nerve Lesions in the Lower Limb. Techniques in Foot & Ankle Surgery. 2008/12;7(4):224-237.
Lisle DA, Johnstone SA. Usefulness of muscle denervation as an MRI sign of peripheral nerve pathology. Australas Radiol. Dec 2007;51(6):516-26. [Medline].
Krishnan AV, Lin CS, Park SB, Kiernan MC. Assessment of nerve excitability in toxic and metabolic neuropathies. J Peripher Nerv Syst. Mar 2008;13(1):7-26. [Medline].
Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. Dec 1999;83(3):389-400. [Medline].
Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. Jul 2008;31(7):1448-54. [Medline].
Azoulay D, Samuel D, Castaing D, et al. Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy. J Am Coll Surg. Dec 1999;189(6):584-93. [Medline].
Kaminski HJ, Ruff RL. Neurologic complications of endocrine diseases. Neurol Clin. Aug 1989;7(3):489-508. [Medline].
Burn DJ, Bates D. Neurology and the kidney. J Neurol Neurosurg Psychiatry. Dec 1998;65(6):810-21. [Medline].
Lagueny A. [Metabolic and nutritional neuropathies]. Rev Prat. Apr 1 2000;50(7):731-5. [Medline].
Parry GJ. Management of diabetic neuropathy. Am J Med. Aug 30 1999;107(2B):27S-33S. [Medline].
| Small-Fiber Sensory | Large-Fiber Sensory | Autonomic |
| Burning pain | Loss of vibration | Heart rate changes |
| Cutaneous allodynia | Proprioception loss | Postural blood pressure change |
| Paresthesias | Loss of reflexes | Abnormal sweating |
| Lancinating pain | Slowed NCVs | Gastroparesis |
| Loss pain/temperature | Sensory ataxia | Impotence |
| Foot ulcers | Weakness | Abnormal ejaculation |
| Visceral pain loss | ||
| * Modified from Apfel, 1999.[13] | ||

